ArticleLeukemia research2013
Distinguishing hairy cell leukemia variant from hairy cell leukemia: development and validation of diagnostic criteria.
Article in Leukemia research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 2 syntheses or guidelines pooled it, 123 citations in OpenAlex.
- [Chinese guideline for diagnosis and treatment of hairy cell leukemia (2023)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2023Guideline
- Recommendations of the SFH (French Society of Haematology) for the diagnosis, treatment and follow-up of hairy cell leukaemia.Annals of hematology · 2014Guideline
- CD25-Targeted Aptamer-Drug Conjugate for the Treatment of CD25-Expressing Hematological Malignancies.Pharmaceutics · 2026Article
- Hairy Cell Leukemia: Clinical Characteristics and Outcomes from a Single Center in the Middle East and North Africa.Journal of blood medicine · 2026Article
- Review
- Article
- Review
- CD103-Negative Hairy Cell Leukemia: A Case Report From University Teaching Hospital, Zambia.Case reports in medicine · 2025Article
- Cell therapy for a rare disease- hairy cell leukemia variant.Oncoimmunology · 2024Article
- Hairy cell leukemia - etiopathogenesis, diagnosis and modern therapeutic approach.Biochemia medica · 2024Review
- Untangling hairy cell leukaemia (HCL) variant and other HCL-like disorders: Diagnosis and treatment.Journal of cellular and molecular medicine · 2024Review
- Non-V600EEJHaem · 2024Article
- [The value of CD200 in differential diagnosis of classic hairy cell leukemia and variant hairy cell leukemia].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2023Article
- Flow Cytometry of CD5-Positive Hairy Cell Leukemia.Molecular diagnosis & therapy · 2023Article
- Article
- The many faces of nodal and splenic marginal zone lymphomas. A report of the 2022 EA4HP/SH lymphoma workshop.Virchows Archiv : an international journal of pathology · 2023Review
- A case report of early diagnosis of asymptomatic hairy cell leukemia using flow cytometry.Frontiers in immunology · 2023Article
- Broadening the horizon: potential applications of CAR-T cells beyond current indications.Frontiers in immunology · 2023Review
- Development of a distributed international patient data registry for hairy cell leukemia.Leukemia & lymphoma · 2022Article
- Purine nucleoside analogs plus rituximab are an effective treatment choice for hairy cell leukemia-variant.Annals of hematology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
Abstract
Hairy cell leukemia (HCL) and hairy cell leukemia-variant (HCL-v) are rare diseases with overlapping clinico-pathological features. We performed flow cytometry analysis (FCM) of 213 cases (169 HCL, 35 HCL-v, 9 splenic marginal zone lymphoma (SMZL)), correlating results with available corresponding clinical and morphological data. FCM distinguished HCL-v from HCL and SMZL based solely upon expression of four antigens (CD11c, CD25, CD103, CD123) combined with B-cell markers (CD19, CD20, CD22). HCL-v expressed bright CD20, bright CD22, CD11c(100%), CD103(100%), dim(40%) or negative(60%) CD123, and uniformly lacked CD25(100%). HCL expressed bright CD20, bright CD22, bright CD11c, bright CD25, CD103, and bright homogeneous CD123(100%). Aberrant expression of CD5(2%/3%), CD10(12%/3%), CD23(21%/11%), CD38(14%/0%), CD2(2%/9%), CD4(0.5%/0%) and CD13(0.5%/3%), was observed in HCL/HCL-v, respectively. SMZL cases were CD103(-) and CD123(-) except for one case with dim CD123. HCL showed significantly greater marrow infiltration over HCL-v. Prominent nucleoli were observed in most HCL-v but rarely in HCL. A third of HCL and HCL-v marrows were hypocellular or aplastic-appearing. Detection of BRAFV600E mutation and annexin A1 were examined in a subset of cases to further validate FCM diagnostic criteria. HCL-v was negative for both annexin A1 (100%) and BRAFV600E mutation (100%), in contrast to HCL (74% positive for annexin A1; 76% positive for BRAFV600E mutation). HCL-v is resistant to traditional HCL therapy, making accurate diagnosis imperative. We have defined FCM criteria for differentiation of HCL-v from HCL and SMZL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.